Haemonetics to acquire remaining shares of Arryx for $26 million

By Lisa Kerner

Charlotte, N.C., June 8 - Haemonetics Corp. has signed a definitive agreement to acquire the outstanding shares of Arryx for $26 million in cash.

The two companies have been collaborating since October 2004 to develop and commercialize proprietary blood separation and processing technologies, according to a company news release.

The transaction is expected to close in the third quarter of this year.

Arryx's proprietary technology uses light to move and manipulate microscopic and nanoscopic objects.

"The acquisition of Arryx is a key component of our strategy to strengthen and diversify our own research initiatives and expand the business by leveraging our core competencies," Haemonetics president and chief executive officer Brad Nutter said in the release.

Arryx's personnel and operations will remain in Chicago.

Haemonetics' new pro forma earnings-per-share guidance is $2.05 to $2.17.

Located in Braintree, Mass., Haemonetics designs and manufactures automated blood processing systems.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.